



# **Health Canada**

Fees Report - Fiscal year 2018 to 2019



Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada's people and to making this country's population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system.

Également disponible en français sous le titre :

Rapport sur les frais - Exercice 2018 à 2019

To obtain additional information, please contact:

Health Canada

Address Locator 0900C2

Ottawa, ON K1A 0K9

Tel.: 613-957-2991

Toll free: 1-866-225-0709

Fax: 613-941-5366 TTY: 1-800-465-7735

E-mail: hc.publications-publications.sc@canada.ca

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2019

Publication date: December 2019

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat.: H1-9/35E-PDF ISBN: 2562-3346 Pub.: 190480

This document is available on the Government of Canada website at www.canada.ca

This document is available in alternative formats upon request.

### TABLE OF CONTENTS

Minister's message	5
About this report	6
Remissions	6
Overall totals, by fee type	7
Totals for fees set by act, regulation or fees notice, by fee grouping	7
Details on each fee set by act, regulation or fees notice	11
Fees for Right to Sell Drugs	11
Fees for Right to Sell a Licensed Class II, III or IV Medical Device	15
Fees for Examination of a Submission — Drugs for Human Use	17
Certificate of Supplemental Protection Application Fees	30
Fees for Examination of an Application for a Medical Device Licence	31
Fees for Examination of a Submission — Drugs for Veterinary Use Only	43
Drug Establishment Licensing Fees	63
Drug Establishment Licensing Fees - Dealer's Licences	68
Medical Device Establishment Licensing Fees	71
Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	72
Annual Charge (for a registered Pest Control Product)	113
Fees Charged for Filing a Claim for Exemption Under the Hazardous Materials Information Re	
Cannabis Fees	116
Endnotes	129

### Minister's message

On behalf of Health Canada, I am pleased to present our report on fees for fiscal year 2018 to 2019, my organization's second annual report under the *Service Fees Act*.

The act provides a modern legislative framework that enables cost-effective delivery of services and, through better reporting to Parliament, improves transparency and oversight.

Last year, a detailed listing of individual fees under the department's authority, along with anticipated increases, was added to the reporting requirements.

This year's report provides more detail on each fee, such as the type and rate of adjustment, the service standard and the performance result. This information provides additional context on each fee, in the spirit of open and transparent fee management.

Additionally, this report includes the revision of the fees in respect of drugs and medical devices. In 2017, Health Canada began engaging with stakeholders to revise fees for regulatory activities related to human drugs, veterinary drugs, and medical devices and effective April 1, 2020, fees, where indicated, will be repealed from the *Financial Administration Act* and set under the authority of the *Food and Drugs Act*. In some instances, new fees are being introduced and some fees are being discontinued.

Cannabis fees were also introduced on October 17, 2018 to support the legalization, strict regulation and restriction on access to cannabis under the *Cannabis Act*.

I welcome the increased transparency and oversight that the *Service Fees Act's* reporting regime embodies, and I am fully committed to transitioning my department to this modern framework. I look forward to continuing to advance my key mandate priorities through collaboration and evidence-based decision-making that will maintain and improve the health and safety of all Canadians.

The Honourable Patty Hajdu Minister of Health

### **About this report**

This report, which is tabled under section 20 of the *Service Fees Act*<sup>i</sup> and section 4.2.8 of the *Directive on Charging and Special Financial Authorities*, contains information about the fees that Health Canada had the authority to charge in the 2018 to 2019 fiscal year.

This report contains information about all fees that are under Health Canada's authority, even if some or all of the fees are collected by another department.

The information reported includes fees that:

- fall under the Service Fees Act
- are exempt from the Service Fees Act

The information covers fees set by:

- contract
- market-base, auction or both
- act, regulation or fees notice

For fees set by the following mechanisms, the report provides totals only:

- contract
- market-base, auction or both

For fees set by act, regulation or fees notice, the report provides totals for fee groupings, as well as detailed information for each individual fee.

Although the fees charged by Health Canada under the *Access to Information Act* are subject to the *Service Fees Act*, they are not included in this report. Information on Health Canada's access to information fees for fiscal year 2018 to 2019 can be found in our access to information report, which is posted on https://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications.html#atip.

#### Remissions

A remission is a partial or full return of a fee to a fee payer who paid for a service for which a department deemed that the service standard was not met.

Under the *Service Fees Act*, departments must develop policies for determining whether a service standard has been met and for determining how much of a fee will be remitted to a fee payer. This requirement does not take effect until April 1, 2020. This report therefore includes **only** 

those remissions issued under Health Canada's enabling legislation. It does not include remissions issued under the *Service Fees Act*.

### Overall totals, by fee type

The following table presents the total revenue, cost and remissions for all fees that Health Canada had the authority to charge in fiscal year 2018 to 2019, by fee type.

#### Overall totals for fiscal year 2018 to 2019, by fee type

Fee type	Revenue (\$)	Cost (\$)	Remissions (\$)
Fees set by contract*	7,851,760	9,193,525	Remissions do not apply to fees set by contract.
Fees set by market base, auction or both	0	0	Remissions do not apply to fees set by market base, auction or both.
Fees set by act, regulation or fees notice	120,090,045	439,609,891	0
Total	127,941,805	448,803,416	0

<sup>\*</sup>Fees set by contract include National Dosimetry Services, Drug Master Files and Certificate of Pharmaceutical Products

## Totals for fees set by act, regulation or fees notice, by fee grouping

The following tables present, for each fee grouping, the total revenue, cost and remissions for all fees that Health Canada had the authority to charge in fiscal year 2018 to 2019 that are set by any of the following:

- act
- regulation
- fees notice

A fee grouping is a grouping of all of the fees that a department has the authority to charge for activities relating to a single business line, directorate or program.

#### Fees for the Right to Sell Drugs: totals for fiscal year 2018 to 2019

Fee grouping	Fees for the Right to Sell Drugs	
Revenue (\$)	Cost (\$)	Remissions (\$)
	3333 (4)	110111100110110 (4)

# Fees for the Right to Sell Licensed Class II, III, or IV Medical Devices: totals for fiscal year 2018 to 2019

Fee grouping	Fees for the Right to Sell Licensed Class II, III, or IV Medical Devices	
Revenue (\$)	Cost (\$)	Remissions (\$)
8,607,115	23,128,668	0

#### Fees for Examination of a Submission — Drugs for Human Use: totals for fiscal year 2018 to 2019

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use	
Revenue (\$)	Cost (\$)	Remissions (\$)
47,907,159	108,715,232	0

#### Certificate of Supplementary Protection Application Fees: totals for fiscal year 2018 to 2019

Fee grouping	Certificate of Supplementary Protection Application Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
229,981	728,757	0

# Fees for the Examination of Medical Device Licence Applications: totals for fiscal year 2018 to 2019

Fee grouping	Fees for the Examination of Medical Device Licence Applications	
Revenue (\$)	Cost (\$)	Remissions (\$)
6,132,439	22,607,534	0

# Fees for Examination of a Submission — Drugs for Veterinary Use Only: totals for fiscal year 2018 to 2019

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Revenue (\$)	Cost (\$)	Remissions (\$)
582,022	6,139,407	0

#### Drug Establishment Licensing Fees: totals for fiscal year 2018 to 2019

Fee grouping	Drug Establishment Licensing Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
16,798,078	32,885,388	0

#### Medical Devices Establishment Licensing Fees: totals for fiscal year 2018 to 2019

Fee grouping	Medical Devices Establishment Licensing Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
8,241,721	9,938,932	0

# Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product: totals for fiscal year 2018 to 2019

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product:	
Revenue (\$)	Cost (\$)	Remissions (\$)
5,397,880	36,746,746	0

#### Annual Charge (for a registered Pest Control Product): totals for fiscal year 2018 to 2019

Fee grouping	Annual Charge (for a registered Pest Control Product)	
Revenue (\$)	Cost (\$)	Remissions (\$)
9,342,992	30,211,129	0

# Fees charged for filing a claim for exemption under the Hazardous Materials Information Review Act: totals for fiscal year 2018 to 2019

Fee grouping	Fees charged for filing a claim for exemption under the Hazardous Materials Information Review Act	
Revenue (\$)	Cost (\$)	Remissions (\$)
458,994	3,246,547	0

#### Cannabis Fees: totals for fiscal year 2018 to 2019

Fee grouping	Cannabis Fees	
Revenue (\$)	Cost (\$)	Remissions (\$)
4,185,748	92,268,533	0

### Details on each fee set by act, regulation or fees notice

This section provides detailed information on each fee that Health Canada had the authority to charge in fiscal year 2018 to 2019 and that was set by any of the following:

- act
- regulation
- fees notice

In most cases, the Department does not currently report revenue collections at the individual fee level. Health Canada is working to implement financial system changes to enable lower-level fee reporting in the future.

### Fees for Right to Sell Drugs

Health Canada monitors human and veterinary drugs on the Canadian market through post-market surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain and sell human and veterinary drugs in Canada.

Fee grouping	Fees for Right to Sell Drugs
Fee	Human drugs
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019 <b>2020 and onwards:</b> fee discontinued April 1 2020
Year introduced	1995
Last year fee-setting authority was amended	2011
Fee type	Other Authorization
Fee amount (\$)	1,176
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020

Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard	120 days to update the Drug Product Database following receipt of a complete Annual Notification Package
Performance result	100% completed on time

Fee grouping	Fees for Right to Sell Drugs
Fee	Human drugs - Disinfectant (item 1)
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020
Fee-setting authority: 2019 and onwards	2020 and onwards:
and onwards	Food and Drugs Act (FDA) iv
	Fees in Respect of Drugs and Medical Devices Order
Year introduced	2019
Last year fee-setting authority was amended	Not Applicable
Fee type	Other Authorization
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, new fee as of April 1 2020
2020 to 2021 fee amount (\$)	1,285
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard	20 days to update the Drug Product Database following receipt of a complete Annual Notification Package
Performance result	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Right to Sell Drugs
Fee	Human drugs - Non-prescription (item 2)
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020
Fee-setting authority: 2019	2020 and onwards:
and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
Year introduced	2019
Last year fee-setting authority was amended	Not Applicable
Fee type	Other Authorization
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate	Not applicable, new fee as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	1,623
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard	20 days to update the Drug Product Database following receipt of a complete Annual Notification Package
Performance result	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Right to Sell Drugs
Fee	Human drugs - Prescription (drug other than one referred to in item 1 or 2)
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020

Fee-setting authority: 2019	2020 and onwards:
and onwards	Food and Drugs Act (FDA) <sup>iv</sup>
	Fees in Respect of Drugs and Medical Devices Order  A
Year introduced	2019
Last year fee-setting authority was amended	Not Applicable
Fee type	Other Authorization
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate	Not applicable, new fee as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	1,836
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard	20 days to update the Drug Product Database following receipt of a complete Annual Notification Package
Performance result	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Right to Sell Drugs	
Fee	Veterinary Drugs	
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA) <sup>ii</sup>	
	<ul> <li>Authority to Sell Veterinary Drug Fees Regulations<sup>vi</sup></li> </ul>	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards:	
	Food and Drugs Act (FDA)iv	
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>	
Year introduced	1995	

Last year fee-setting authority was amended	2019
Fee type	Other Authorization
Fee amount (\$)	250
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	312
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard	120 days to update the Drug Product Database following receipt of a complete Annual Notification Package  * As of April 1 2020 will be 20 days
Performance result	100% completed on time

## Fees for Right to Sell a Licensed Class II, III or IV Medical Device

Health Canada monitors medical devices on the Canadian market through post-market surveillance and compliance and enforcement activities. There is an annual fee for the right to sell a Class II, III, IV medical device.

Fee grouping	Fees for Right to Sell a Licensed Class II, III or IV Medical Device
Fee	Medical Device Right to Sell (if annual gross revenue medical device sales is less than \$20,000)
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019 <b>2020 and onwards:</b> fee discontinued April 1 2020
Year introduced	1999

Last year fee-setting authority was amended	2011
Fee type	Other Authorization
Fee amount (\$)	63
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard	20 days from deadline for receipt of annual notification to update the Medical Devices License Listing (MDALL) database
Performance result	99.94% completed on time

Fee grouping	Fees for Right to Sell a Licensed Class II, III or IV Medical Device
Fee	Medical Device Right to Sell
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA) iv</li> <li>Fees in Respect of Drugs and Medical Devices Order</li> </ul>
Year introduced	1999
Last year fee-setting authority was amended	2019
Fee type	Other Authorization
Fee amount (\$)	383
Total fee revenue (\$)	No data available at this time

Adjustment type	Annual
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	381
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
Service standard	20 days from deadline for receipt of annual notification to update the Medical Devices License Listing (MDALL) database
Performance result	99.94% completed on time

## Fees for Examination of a Submission — Drugs for Human Use

Before a drug is authorized for sale in Canada, Health Canada reviews it to assess its safety, efficacy and quality. Drug products include prescription and non-prescription pharmaceuticals, biologics, disinfectants and sanitizers with disinfectant claims.

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	New active substance
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	348,606
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic

Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	400,288
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	New drug submission (NDS) - 300 Days
Performance result (average)	NDS - Pharmaceuticals(254 Days) Biologics (226 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Clinical or non-clinical data and chemistry and manufacturing data
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	176,569
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	204,197

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	New drug submission (NDS) - 300 Days Supplement to a new drug submission (SNDS) - 300 Days Drug identification number application (DIN A) - 210 Days
Performance result (average)	NDS - Pharmaceuticals(278 Days) Biologics (275 Days) SNDS - Pharmaceuticals(270 Days) Biologics (300 Days) DIN A - Pharmaceuticals(206 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Clinical or non-clinical data only
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)iv</li> <li>Fees in Respect of Drugs and Medical Devices Order</li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	82,410
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	90,864

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	Supplement to a new drug submission (SNDS) - 300 Days Drug identification number application (DIN A) - 210 Days
Performance result (average)	SNDS - Pharmaceuticals(276 Days) Biologics (275 Days) DIN A - Pharmaceuticals(208 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Comparative studies
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	49,811
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	53,836
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020

Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	Abbreviated new drug submission (ANDS) - 180 Days New drug submission (NDS) - 180 Days Supplement to an abbreviated new drug submission (SANDS) - 180 Days Supplement to a new drug submission - 180 Days Drug identification number application (DIN A) - 210 Days
Performance result (average)	ANDS- Pharmaceuticals(168 Days)  NDS - Pharmaceuticals(178 Days)  SANDS- Pharmaceuticals(148 Days)  SNDS - Pharmaceuticals(173 Days) Biologics (179 Days)  DIN A - Pharmaceuticals(202 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Chemistry and manufacturing data only
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>jv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	23,551
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	27,587

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average	Abbreviated new drug submission (ANDS) - 180 Days
time to complete Review 1)	New drug submission (NDS) - 180 Days
	Supplement to an abbreviated new drug submission (SANDS)- 180 Days
	Supplement to a new drug submission - 180 Days
	Drug identification number application (DIN A) - 210 Days
Performance result (average)	ANDS - Pharmaceuticals(170 Days)
	NDS - Pharmaceuticals(178 Days)
	SANDS - Pharmaceuticals(155 Days)
	SNDS - Pharmaceuticals (162 Days) Biologics (143 Days)
	DIN A- Pharmaceuticals(194 Days) Biologics (207 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
i ee grouping	Tees for Examination of a Submission — Brugs for Human Ose
Fee	Clinical or non-clinical data only, in support of safety upgrades to the labelling
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020
Fee-setting authority: 2019	2020 and onwards:
and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	2019
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fees as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate	Not applicable, new fees as of April 1 2020

(% or formula)	
2020 to 2021 fee amount (\$)	19,442
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fees as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
Service standard (average time to complete Review 1)	120 Days
Performance result (average)	Not applicable, new fees as of April 1 2020

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Published data only
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards: fee discontinued April 1 2020
Year introduced	1995
Last year fee-setting authority was amended	2011
Fee type	Service
Fee amount (\$)	19,530
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020

Service standard (average time to complete Review 1)	Supplement to a new drug submission (SNDS)- 300 Days Drug identification number application (DIN A) - 210 Days
Performance result (average)	SNDS - Pharmaceuticals (271 Days) Biologics (273 Days) DIN A - Pharmaceuticals(189 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Switch from prescription to non-prescription status
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards: fee discontinued April 1 2020
Year introduced	1995
Last year fee-setting authority was amended	2011
Fee type	Service
Fee amount (\$)	47,421
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate	Not applicable, fee discontinued as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard (average time to complete Review 1)	Supplement to a new drug submission (SNDS) - 180 Days
Performance result (average)	Supplement to a new drug submission - 179 Days

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Labelling only
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)iv</li> <li>Fees in Respect of Drugs and Medical Devices Orderv</li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	3,174
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	3,816
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	New drug submission (NDS) - 60 Days Supplement to a new drug submission (SNDS) - 60 Days Abbreviated new drug submission (ANDS) - 60 Days Supplement to an abbreviated new drug submission (SANDS)- 60 Days Drug identification number application (DIN A)- 180 Days * As of April 2020 will be 120 Days for all types
Performance result (average)	NDS - Pharmaceuticals(50 Days) Biologics (59 Days) SNDS - Pharmaceuticals(52 Days) Biologics (58 Days) ANDS - Pharmaceuticals(40 Days)

SANDS - Pharmaceuticals(37 Days)
DIN A - Pharmaceuticals(159 Days) Biologics (105 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Labelling only (generic drugs)
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020
Fee-setting authority: 2019 and onwards	2020 and onwards:
and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	2019
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate	Not applicable, new fee as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	2,010
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
Service standard (average time to complete Review 1)	120 Days
Performance result (average)	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Administrative submission
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA) <sup>ii</sup>

	Fees in Respect of Drugs and Medical Devices
	Regulations <sup>iii</sup>
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards:
	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order<sup>N</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	331
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	432
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average	Abbreviated new drug submission (ANDS)- 45 Days
time to complete Review 1)	New drug submission (NDS)- 45 Days
	Supplement to a new drug submission (SNDS) - 45 Days
	Supplement to an abbreviated new drug submission (SANDS)- 45 Days
	Drug identification number application (DIN A & B)- 45 Days
	Drug identification number application - Disinfectant (DIN D) - 45 Days
Performance result (average)	ANDS - Pharmaceuticals(30 Days)
	NDS - Pharmaceuticals(28 Days)
	SNDS - Pharmaceuticals(24 Days)
	SANDS - Pharmaceuticals(26 Days)
	DIN A & B - Pharmaceuticals(25 Days) Biologics (40 Days)
	DIN D - Pharmaceuticals(34 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Disinfectant - full review
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	4,392
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	5,712
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average	New drug submission (NDS) - 300 Days
time to complete Review 1)	Drug identification number application (Disinfectant 210) (DIN D 210) - 210 Days
Performance result (average)	NDS - Pharmaceuticals(294 Days)
	DIN D 210 - Pharmaceuticals(204 Days)

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Labelling only (disinfectants)
Fee-setting authority: 2018 to 2019	Not applicable, new fee as of April 1 2020
Fee-setting authority: 2019 and onwards	<ul> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	2019
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, new fee as of April 1 2020
2020 to 2021 fee amount (\$)	2,507
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order*
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	120 Days
Performance result (average)	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Examination of a Submission — Drugs for Human Use
Fee	Drug identification number application – labelling standards
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019 <b>2020 and onwards:</b>

	Food and Drugs Act (FDA)iv
	Fees in Respect of Drugs and Medical Devices Order
Year introduced	1995
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	1,761
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	1,616
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average time to complete Review 1)	Drug identification number application (DIN A) - 45 Days  Drug identification number application -Disinfectant (DIN D)- 45 Days  Drug identification number application - Category IV (DIN F) - 45 Days  * As of April 2020 it will be 60 Days for all types
Performance result (average)	DIN A - Pharmaceuticals(41 Days) DIN D - Pharmaceuticals(40 Days) DIN F - Pharmaceuticals(41 Days)

## **Certificate of Supplemental Protection Application Fees**

In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis (of its own kind) protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs.

Fee grouping	Certificate of Supplemental Protection Application Fees
Fee	Certificate of Supplemental Protection Application Fees

Fee-setting authority: 2018 to 2019	Patent Act <sup>vii</sup> Certificate of Supplementary Protection Regulations <sup>viii</sup>
Fee-setting authority: 2019 and onwards	<ul> <li>Patent Act<sup>vii</sup></li> <li>Certificate of Supplementary Protection Regulations<sup>viii</sup></li> </ul>
Year introduced	2017
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	9,192
Total fee revenue (\$)	229,981
Adjustment type	Annual
Adjustment rate	2% rounded up to the nearest dollar
(% or formula)	
2020 to 2021 fee amount (\$)	9,564
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1 2020
Fee-adjustment authority	Certificate of Supplementary Protection Regulations <sup>viii</sup>
Service standard (average)	60 Days for the first eligibility decision
Performance result (average)	40 Days

## Fees for Examination of an Application for a Medical Device Licence

The Medical Device Licence Application Fees apply only to Class II, III and IV medical device licence applications. The following types of medical devices are exempt from medical device licensing and therefore no fees apply: Class I medical devices; custom-made medical devices; medical devices for special access; medical devices for investigational testing involving human subjects.

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class II licence
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>

Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	397
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	450
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	15 Days to complete Review 1
Performance result (average)	9 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class II licence amendment
Fee-setting authority: 2018 to 2019	Not applicable, new fee as of April 1 2020
Fee-setting authority: 2019 and onwards	<ul> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	2019

Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate	Not applicable, new fee as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	272
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order*
Service standard (average)	15 Days to complete Review 1
Performance result (average)	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class III licence
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)iv</li> <li>Fees in Respect of Drugs and Medical Devices Orderv</li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	5,691
Total fee revenue (\$)	No data available at this time

Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	7,477
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	60 Days to complete Review 1
Performance result (average)	49 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class III licence (near patient)
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	9,687
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020

2020 to 2021 fee amount (\$)	12,851
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order*  Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	60 Days to complete Review 1
Performance result (average)	49 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class III licence amendment - changes in manufacturing
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)iv</li> <li>Fees in Respect of Drugs and Medical Devices Order</li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	1,433
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	1,903
Future fee-adjusted amount (\$)	Not applicable

Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	60 Days to complete Review 1
Performance result (average)	40 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class III licence amendment - significant changes not related to manufacturing
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	5,330
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	6,608
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.

Service standard (average)	60 Days to complete Review 1
Performance result (average)	48 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class IV licence
Fee-setting authority: 2018 to 2019	Not applicable, new fee as of April 1 2020
Fee-setting authority: 2019	2020 and onwards:
and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order<sup>N</sup></li> </ul>
Year introduced	2019
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate	Not applicable, new fee as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	24,345
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
	Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	75 Days to complete Review 1
Performance result (average)	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class IV licence
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards: fee discontinued April 1 2020
Year introduced	1998
Last year fee-setting authority was amended	2011
Fee type	Service
Fee amount (\$)	13,235
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard (average)	75 Days to complete Review 1
Performance result (average)	58 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Class IV - Licence Application (Devices that contain Human-Animal Tissue)
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>

Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards: fee discontinued April 1 2020
Year introduced	1998
Last year fee-setting authority was amended	2011
Fee type	Service
Fee amount (\$)	12,347
Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate	Not applicable, fee discontinued as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard (average)	75 Days to complete Review 1
Performance result (average)	54 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Class IV - Licence Application (Near patient In Vitro Diagnostic Device)
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019 <b>2020 and onwards:</b> fee discontinued April 1 2020
Year introduced	1998
Last year fee-setting authority was amended	2011
Fee type	Service
Fee amount (\$)	22,560

Total fee revenue (\$)	No data available at this time
Adjustment type	Not applicable, fee discontinued as of April 1 2020
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020
2020 to 2021 fee amount (\$)	Not applicable, fee will be discontinued as of April 1 2020
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee discontinued as of April 1 2020
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020
Service standard (average)	75 Days to complete Review 1
Performance result (average)	n/a no applications completed

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class IV licence amendment - changes in manufacturing
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>2019 to 2020: same as 2018 to 2019</li> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	1,433
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020

2020 to 2021 fee amount (\$)	1,903
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order*  Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	75 Days to complete Review 1
Performance result (average)	49 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class IV licence amendment - significant changes not related to manufacturing
Fee-setting authority: 2018 to	Financial Administration Act (FAA) <sup>ii</sup>
2019	Fees in Respect of Drugs and Medical Devices Regulations
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards:
	<ul> <li>Food and Drugs Act (FDA)iv</li> </ul>
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order*</li> </ul>
Year introduced	1998
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	6,073
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate	Not applicable, fee updated as of April 1 2020
(% or formula)	
2020 to 2021 fee amount (\$)	8,057
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020

Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over four years as well as the annual CPI adjustment.
Service standard (average)	75 Days to complete Review 1
Performance result (average)	51 Days to complete Review 1

Fee grouping	Fees for Examination of an Application for a Medical Device Licence
Fee	Applications for Class II, III or IV licence or licence amendment - private label medical device
Fee-setting authority: 2018 to 2019	Not applicable, new fee as of April 1 2020
Fee-setting authority: 2019	2020 and onwards:
and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
Year introduced	2019
Last year fee-setting authority was amended	Not applicable
Fee type	Service
Fee amount (\$)	Not applicable, new fee as of April 1 2020
Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate (% or formula)	Not applicable, new fee as of April 1 2020
2020 to 2021 fee amount (\$)	147
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
Service standard (average)	15 Days to complete Review 1
Performance result (average)	Not applicable, new fee as of April 1 2020

# Fees for Examination of a Submission — Drugs for Veterinary Use Only

Before a veterinary drug is authorized for sale in Canada, Health Canada reviews it to assess it efficacy and safety in the intended species as well as human safety. Fees are calculated on a component basis.

Fee grouping	Fees for Examination of a Submission — Drugs for Veteri	inary Use	
Fee	Application for drug identification number	Application for drug identification number	
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>	• •	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019		
and onwards	2020 and onwards :		
	Food and Drugs Act (FDA)iv		
	Fees in Respect of Drugs and Medical Devices C	)rder <sup>v</sup>	
Year introduced	1996		
Last year fee-setting authority was amended	2019		
Fee type	Service		
Fee amount (\$)	Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required	720	
	Published references or other data	500	
	Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug	250	
Total fee revenue (\$)	No data available at this time		
Adjustment type	Periodic		
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020		
2020 to 2021 fee amount (\$)	Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required	918	
	Published references or other data	638	

	Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug	320
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order	
	Fees phased in over seven years as well as the annual ( adjustment.	JPI .
	adjustment.	
Service standard (average)	120 Days to complete Review 1	
Performance result (average)	93 Days to complete Review 1	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Fee	Notification – veterinary health product	
Fee-setting authority: 2018 to 2019	Not applicable, new fee as of April 1 2020	
Fee-setting authority: 2019 and onwards	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>	
Year introduced	2019	
Last year fee-setting authority was amended	Not applicable	
Fee type	Service	
Fee amount (\$)	Not applicable, new fee as of April 1 2020	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	Not applicable, new fee as of April 1 2020	
2020 to 2021 fee amount (\$)	Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product	

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, new fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over seven years as well as the annual CPI adjustment.
Service standard (average)	30 Days to process notification
Performance result (average)	Not applicable, new fee as of April 1 2020

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Fee	New drug submission	
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>	
Fee-setting authority: 2019 and onwards	2019 to 2020: same as 2018 to 2019 2020 and onwards:  • Food and Drugs Act (FDA)iv  • Fees in Respect of Drugs and Medical Devices Orderv	
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.)	15,980
	Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	9,680
	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species	23,240

	Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	31,470
	Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	2,900
	Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	480
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	21,790
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	29,050
	For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration	2,900
	For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species	14,520
	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	4,840
	Chemistry and manufacturing data to support one strength of a single dosage form	4,840
	Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the above item	2,420
	Documentation to support a change of manufacturer	250
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	

2020 to 2021 fee amount (\$)	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.)	20,375
	Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	12,342
	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species	29,631
	Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	40,125
	Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	3,698
	Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	612
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	27,783
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	37,040
	For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration	3,698
	For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species	18,513

	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	6,171
	Chemistry and manufacturing data to support one strength of a single dosage form	6,171
	Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the above item	3,086
	Documentation to support a change of manufacturer	320
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order	
	Fees phased in over seven years as well as the annual CPI adjustment.	
Service standard (average)	300 Days to complete Review 1 (other than Administrative	ve NDS)
	90 Days to complete review for Administrative NDS	
Performance result (average)	262 Days to complete Review 1 (other than Administrative NDS) 19 Days to complete review for Administrative NDS	

Fee grouping	Fees for Examination of a Submission — Drugs for Veter Only	rinary Use
Fee	Supplement to a new drug submission	
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA) <sup>ii</sup>	
2019	<ul> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards :	
	<ul> <li>Food and Drugs Act (FDA)iv</li> </ul>	
	Fees in Respect of Drugs and Medical Devices Order	
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Efficacy data to support an additional indication in one animal species	12,590

Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species  Efficacy and safety data (in the intended species) to support an indication in another animal species  Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.  Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species  Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species  Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species  Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue init and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal period size required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a change in formulation or dosage fo		
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.  Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species  Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species  Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal period is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process	support a single route of administration and dosage form for an antiparasitic drug in one non-food animal	9,680
support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.  Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species  Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species  Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420		15,980
support a growth promotion or production enhancement indication in one animal species  Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species  Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a  2,420	support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications	23,240
support the concurrent use of two drugs approved for the same animal species  Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	support a growth promotion or production	31,470
bioavailability) data to support an additional route of administration  Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	support the concurrent use of two drugs approved for	7,740
bioavailability) data to support each additional strength  For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	bioavailability) data to support an additional route of	2,900
to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species  For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420		480
depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species  For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	to establish a new withdrawal period for a change in the dosage or route of administration of an approved	2,900
a change of an established acceptable daily intake, maximum residue limit and withdrawal period  For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an	14,520
food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required  Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	a change of an established acceptable daily intake,	7,260
change in the source of a medicinal ingredient or its manufacturing process  Chemistry and manufacturing data to support a 2,420	food-producing animals, residue depletion studies to determine if an extension to existing withdrawal	5,810
	change in the source of a medicinal ingredient or its	4,840
		2,420

	Chemistry and manufacturing data to support a change in packaging or in the sterilization process	1,930
	Chemistry and manufacturing data to support an extension of the expiry dating	1,450
	Chemistry and manufacturing data to support the concurrent use of two drugs	1,450
	Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms	480
	Documentation to support a change to the name of a manufacturer or the brand name of a drug	250
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Efficacy data to support an additional indication in one animal species	16,053
	Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	12,342
	Efficacy and safety data (in the intended species) to support an indication in another animal species	20,375
	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.	29,631
	Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	40,125
	Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species	9,869
	Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration	3,698
	Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength	612

	For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species	3,698
	For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species	18,513
	For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period	9,257
	For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required	7,409
	Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process	6,171
	Chemistry and manufacturing data to support a change in formulation or dosage form	3,086
	Chemistry and manufacturing data to support a change in packaging or in the sterilization process	2,462
	Chemistry and manufacturing data to support an extension of the expiry dating	1,850
	Chemistry and manufacturing data to support the concurrent use of two drugs	1,850
	Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms	612
	Documentation to support a change to the name of a manufacturer or the brand name of a drug	320
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order	
	Fees phased in over seven years as well as the annual C adjustment.	:PI
Service standard (average)	240 Days to complete Review 1	

Performance result (average)	186 Days to complete Review 1
------------------------------	-------------------------------

Fee grouping	Fees for Examination of a Submission — Drugs for Veter Only	inary Use
Fee	Abbreviated new drug submission	
Fee-setting authority: 2018 to	Financial Administration Act (FAA) <sup>ii</sup>	
2019	Veterinary Drug Evaluation Fees Regulationsix	
Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards :	
	Food and Drugs Act (FDA)iv	
	Fees in Respect of Drugs and Medical Devices C	Order <sup>v</sup>
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Any applicable component listed under Supplement to a submission	new drug
	Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	2,900
	For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product	2,900
	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	4,840
	Chemistry and manufacturing data to support a single dosage form	4,840
	Documentation to support:	250
	a) a change of manufacturer, in the case of an abbreviated new drug submission; or	
	(b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	

Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Any applicable component listed under Supplement to a submission	new drug
	Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	3,698
	For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product	3,698
	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	6,171
	Chemistry and manufacturing data to support a single dosage form	6,171
	Documentation to support:	320
	a) a change of manufacturer, in the case of an abbreviated new drug submission; or	
	(b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order   Output  Devices Order  Output  Devices Order  Devices Order	
	Fees phased in over seven years as well as the annual Cadjustment.	CPI
Service standard (average)	300 Days to complete Review 1	
Performance result (average)	269 Days to complete Review 1	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only
Fee	Supplement to an abbreviated new drug submission
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>

Fee-setting authority: 2019 and onwards	2019 to 2020: same as 2018 to 2019 2020 and onwards :	
	<ul> <li>Food and Drugs Act (FDA)<sup>jv</sup></li> <li>Fees in Respect of Drugs and Medical Devices 0</li> </ul>	Order <sup>v</sup>
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Any applicable component listed under Supplement to a submission	new drug
	Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	2,900
	For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product	2,900
	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	4,840
	Chemistry and manufacturing data to support a single dosage form	4,840
	Documentation to support:	250
	a) a change of manufacturer, in the case of an abbreviated new drug submission; or	
	(b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Any applicable component listed under Supplement to a submission	new drug
	Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form	3,698
	For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each	3,698

	species falls within the conditions of use for the Canadian reference product	
	Chemistry and manufacturing data for a non- compendial medicinal ingredient of a drug	6,171
	Chemistry and manufacturing data to support a single dosage form	6,171
	Documentation to support:	320
	a) a change of manufacturer, in the case of an abbreviated new drug submission; or	
	(b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order	
	Fees phased in over seven years as well as the annual C	:PI
	adjustment.	
Service standard (average)	240 Days to complete Review 1	
Performance result (average)	117 Days to complete Review 1	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only
Fee	Preclinical submission
Fee-setting authority: 2018 to	Financial Administration Act (FAA) <sup>ii</sup>
2019	<ul> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards :
	Food and Drugs Act (FDA)iv
	<ul> <li>Fees in Respect of Drugs and Medical Devices Order</li> </ul>
Year introduced	1996
Last year fee-setting authority was amended	2019
Fee type	Service

Fee amount (\$)	Efficacy and safety ( in the intended species) and protocol to support the conduct of clinical studies relative to a single dose form, route of administration and indication in one species	4,840
	Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated	3,870
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	14,520
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	21,790
	For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	29,050
	For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species	7,260
	Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient	4,840
	Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient	2,420
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	

Efficacy and safety ( in the intended species) and protocol to support the conduct of clinical studies relative to a single dose form, route of administration and indication in one species  Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated  For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and	6,171 4,935 18,513
clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated  For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and	
residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and	18,513
residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species  For food-producing animals, toxicity, metabolism and	
	27,783
residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	37,040
For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species	9,257
Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient	6,171
Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient	3,086
Future fee-adjusted amount (\$)  Not applicable	
Adjustment date Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority Fees in Respect of Drugs and Medical Devices Order	

	Fees phased in over seven years as well as the annual CPI adjustment.
Service standard (average)	60 Days to review application
Performance result (average)	n/a for 2018-19

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Fee	Sale of new drug for emergency treatment	
Fee-setting authority: 2018 to	Financial Administration Act (FAA) <sup>ii</sup>	
2019	Veterinary Drug Evaluation Fees Regulationsix	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards :	
	<ul> <li>Food and Drugs Act (FDA)iv</li> </ul>	
	Fees in Respect of Drugs and Medical Devices 0	Order <sup>v</sup>
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Information to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal	50
	Information to support the sale of a drug to be used in the emergency treatment of a food-producing animal	100
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Information and material to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal	51
	Information and material to support the sale of a drug to be used in the emergency treatment of a food-producing animal	102

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order
Service standard (average)	2 business days to review application
Performance result (average)	<2 business days to review application

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only	
Fee	Experimental studies certificate	
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA)ii	
	Veterinary Drug Evaluation Fees Regulationsix	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards :	
	<ul> <li>Food and Drugs Act (FDA)iv</li> </ul>	
	Fees in Respect of Drugs and Medical Devices (	Order <sup>v</sup>
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal	960
	Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal	480
	Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal	2,900

	Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal	480
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal	980
	Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal	490
	Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal	2,958
	Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal	490
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order	
Service standard (average)	60 Days to review application	
Performance result (average)	42 Days to review application	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only
Fee	Notifiable change
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA)ii

	Veterinary Drug Evaluation Fees Regulations <sup>ix</sup>	
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019	
and onwards	2020 and onwards :	
	Food and Drugs Act (FDA)iv	
	Fees in Respect of Drugs and Medical Devices Order	
Year introduced	1996	
Last year fee-setting authority was amended	2019	
Fee type	Service	
Fee amount (\$)	Information and material to support an application for Notifiable Change 1,300	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020	
2020 to 2021 fee amount (\$)	Information and material to support an application for a notifiable change 1,658	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee updated as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order⁴	
	Fees phased in over seven years as well as the annual CPI	
	adjustment.	
Service standard (average)	90 Days to review application for Notifiable Changes	
Performance result (average)	62 Days to review application for Notifiable Changes	

Fee grouping	Fees for Examination of a Submission — Drugs for Veterinary Use Only
Fee	Protocol
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Veterinary Drug Evaluation Fees Regulations<sup>ix</sup></li> </ul>

Fee-setting authority: 2019 and onwards	<b>2019 to 2020</b> : same as 2018 to 2019 <b>2020 and onwards</b> :
	Food and Drugs Act (FDA)i
	Fees in Respect of Drugs and Medical Devices Order
Year introduced	1996
Last year fee-setting authority was amended	2019
Fee type	Service
Fee amount (\$)	A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate
Total fee revenue (\$)	No data available at this time
Adjustment type	Periodic
Adjustment rate (% or formula)	Not applicable, fee updated as of April 1 2020
2020 to 2021 fee amount (\$)	A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, fee updated as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over seven years as well as the annual CPI adjustment.
Service standard (average)	60 Days to review package for Protocol
Performance result (average)	60 Days to review package for Protocol

### **Drug Establishment Licensing Fees**

Any person in Canada must obtain a Drug Establishment Licence (DEL) if they are engaged in any of the six regulated activities (fabricate, import, distribute, wholesale, package/label, and test) with respect to human and/or veterinary drugs. A fee is charged for the examination of a DEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The DEL fee is calculated on a component basis; therefore, the fee amount varies by application. A DEL fee is charged for the application for a new DEL, an annual licence review of a DEL, certain amendments to a DEL, reinstatement of a suspended DEL, or reactivation of a cancelled or withdrawn DEL.

As of April 1, 2020, a more simplified DEL fee regime will be introduced, as indicated in the tables below.

Fee grouping	Drug Establishment Licence Fees	
Fee	Human Drug Establishment Licence Fee (component based)	
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>	
Fee-setting authority: 2019 and onwards	2019 to 2020: same as 2018 to 2019 2020 and onwards: fee discontinued April 1 2020	
Year introduced	1998	
Last year fee-setting authority was amended	2011	
Fee type	Licence	
Fee amount (\$)	Fabrication - Basic Fee	17,751
	Fabrication - Each Additional Category	4,449
	Dosage Form Classes:	
	Fabrication - Two classes	8,883
	Fabrication - Three classes	17,751
	Fabrication - Four classes	22,198
	Fabrication - Five classes	26,629
	Fabrication - Six classes	31,064
	Fabrication - Each additional class	1,783
	Fabrication - Sterile dosage forms	8,883
	Packaging/labelling - Basic Fee	11,869

	Packaging/labelling - Each Additional Category	2,966
	Packaging/labelling - Two classes	5,920
	Packaging/labelling - Three or more classes	8,883
	Importation/Distribution - Basic Fee	7,402
	Importation/Distribution - Each Additional Category	1,853
	Importation/Distribution - Two classes	3,703
	Importation/Distribution - Three or more classes	7,402
	Importation/Distribution - Each fabricator	1,783
	Importation/Distribution - Each additional dosage form class for each fabricator	899
	Distribution and Wholesaling Fee	4,449
	Testing - Testing Fee	2,966
	Drug Analysis Component - Vaccines	29,582
	Drug Analysis Component - Schedule D Drugs which are not vaccines or whole blood and its components	11,836
	Drug Analysis Component - Drugs for human use that are prescription drugs, controlled drugs or narcotics	8,883
	Drug Analysis Component - Drugs for human use, not included in any other item, for which a drug identification number has been assigned	4,449
Total fee revenue (\$)	No data available at this time	1
Adjustment type	Not applicable, fee discontinued as of April 1 2020	
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020	
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee discontinued as of April 1 2020	
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020	
Service standard	250 Calendar days to issue/ renew license	

Performance result	Average number of days applicable to the DEL fee grouping
	(human and veterinary): 75 days

Fee grouping	Drug Establishment Licence Fees	
Fee	Human Drug Establishment Licence Fee (component based)	
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020	
Fee-setting authority: 2019 and onwards	<ul> <li>2020 and onwards:</li> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Fees in Respect of Drugs and Medical Devices Order<sup>v</sup></li> </ul>	
Year introduced	2019	
Last year fee-setting authority was amended	Not Applicable	
Fee type	Licence	
Fee amount (\$)	Not applicable, new fees as of April 1 2020	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, new fees as of April 1 2020	
2020 to 2021 fee amount (\$)	Fabrication - Sterile dosage form	41,626
	Importation	27,359
	Fabrication - non-sterile dosage form	27,000
	Distribution	12,560
	Wholesaling	4,937
	Packaging/labelling	6,061
	Testing	2,560
	Building outside Canada (each)	918
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, new fees as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>N</sup> Fees phased in over four years as well as the annual CP adjustment	I

Service standard	250 Calendar days to issue/ renew license
Performance result	No performance result is available, since the new fee will be introduced on April 1 2020

Fee grouping	Drug Establishment Licence Fees	
Fee	Veterinary Drug Establishment Licence Fee (component based)	
Fee-setting authority: 2018 to 2019	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> <li>Establishment Licensing Fees (Veterinary Drugs)         Regulations<sup>x</sup></li> </ul>	
Fee-setting authority: 2019 2019 to 2020: same as 2018 to 2019		
and onwards	2020 and onwards: fee discontinued April 1 2020	
Year introduced	1998	
Last year fee-setting authority was amended	Not Applicable	
Fee type	Licence	
Fee amount (\$)	Fabrication - Basic Fee	6,000
	Fabrication - Each Additional Category	1,500
	Dosage Form Classes:	
	Fabrication - Two classes	3,000
	Fabrication - Three classes	6,000
	Fabrication - Four classes	7,500
	Fabrication - Five classes	9,000
	Fabrication - Six classes	10,500
	Fabrication - Each additional class	600
	Fabrication - Sterile dosage forms	3,000
	Packaging/Labelling - Basic Fee	4,000
	Packaging/Labelling - Each Additional Category	1,000
	Packaging/Labelling - Two classes	2,000
	Packaging/Labelling - Three or more classes	3,000
	Importation/Distribution - Basic Fee	2,500
	Importation/Distribution - Each Additional Category	625
	Importation/Distribution - Two classes	1,250

	Importation/Distribution - Three or more classes	2,500
	Importation/Distribution - Each fabricator	600
	Importation/Distribution - Each additional dosage form class for each fabricator	300
	Distribution and Wholesaling - Distribution and Wholesaling Fee	1,500
	Testing - Testing Fee	1,000
	Drug Analysis Component - Drug Identification Numbers for Veterinary Use	250
Total fee revenue (\$)	No data available at this time	
Adjustment type	Not applicable, fee discontinued as of April 1 2020	
Adjustment rate (% or formula)	Not applicable, fee discontinued as of April 1 2020	
2020 to 2021 fee amount (\$)	Not applicable, fee discontinued as of April 1 2020	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, fee discontinued as of April 1 2020	
Fee-adjustment authority	Not applicable, fee discontinued as of April 1 2020	
Service standard	250 Calendar days to issue/ renew license	
Performance result	Average number of days applicable to the DEL fee grouping (human and veterinary): 75 days	)

Fee grouping	Drug Establishment Licence Fees
Fee	Veterinary Drug Establishment Licence Fee (component based)
Fee-setting authority: 2018 to 2019	Not applicable, new fees as of April 1 2020
Fee-setting authority: 2019 and onwards	Food and Drugs Act (FDA) <sup>iv</sup> Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>
Year introduced	2019
Last year fee-setting authority was amended	Not Applicable
Fee type	Licence
Fee amount (\$)	Not applicable, new fees as of April 1 2020

Total fee revenue (\$)	No data available at this time	
Adjustment type	Periodic	
Adjustment rate (% or formula)	Not applicable, new fees as of April 1 2020	
2020 to 2021 fee amount (\$)	Fabrication - Sterile dosage form	40,198
	Importation	10,715
	Fabrication - non-sterile dosage form	8,782
	Distribution	4,835
	Wholesaling	1,933
	Packaging/labelling	6,061
	Testing	1,315
	Building outside Canada (each)	765
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	Not applicable, new fees as of April 1 2020	
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup> Fees phased in over seven years as well as the annual CPI adjustment	
Service standard	250 Calendar days to issue/ renew license	
Performance result	No performance result is available, since the new fee will be introduced on April 1 2020	

## **Drug Establishment Licensing Fees - Dealer's Licences**

Fees for the examination of an application for a new dealer's licence or the renewal of a dealer's licence; issued under the Narcotic Control Regulations and Part G of the Food and Drug Regulations. There is no fee associated with the application for a new or renewal of a controlled substances licence issued under the Benzodiazepines and Other Targeted Substances Regulations and Part J of the Food and Drug Regulations.

Fee grouping	Drug Establishment Licence Fees
Fee	Dealer's Licence Fees - Human Drugs
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices Regulations<sup>iii</sup></li> </ul>

Fee-setting authority: 2019 and onwards	2019 to 2020: same as above 2020 and onwards:  • Financial Administration Act (FAA) <sup>ii</sup> • Fees in Respect of a Dealer's Licences Regulations (SOR/2019-134) <sup>xi</sup>
Year introduced	1998
Last year fee-setting authority was amended	2011
Fee type	Licence
Fee amount (\$)	5,184
Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)
2020 to 2021 fee amount (\$)	5,394
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1 2020
Fee-adjustment authority	Fees in Respect of a Dealer's Licences Regulations (SOR/2019-134) <sup>xi</sup>
Service standard	270 Calendar days to issue a decision on an application for a <b>new</b> dealer's licence for controlled substances, from the receipt of a complete application  90 Calendar days to issue a decision on an application to <b>renew</b> a dealer's licence for controlled substances, from the receipt of a complete application
Performance result	New: 56% of applications were processed within the service standard Renew: 100% of applications were processed within the service standard

Fee grouping	Drug Establishment Licence Fees
Fee	Dealer's License Fees - Veterinary Drugs
Fee-setting authority: 2018 to 2019	Financial Administration Act (FAA) <sup>ii</sup>

Fee-setting authority: 2019 and onwards	<ul> <li>Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations<sup>xii</sup></li> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations<sup>xii</sup></li> </ul>	
Year introduced	1998	
Last year fee-setting authority was amended	Not Applicable	
Fee type	Licence	
Fee amount (\$)	1,750	
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2019 April All-items Consumer Price Index for Canada (2%) on current fees	
2020 to 2021 fee amount (\$)	1,824.27	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1 2020	
Fee-adjustment authority	Section 17 of the Service Fees Act (Consumer Price Index)	
Service standard	270 Calendar days to issue a decision on an application for a <b>new</b> dealer's licence for controlled substances, from the receipt of a complete application  90 Calendar days to issue a decision on an application to <b>renew</b> a dealer's licence for controlled substances, from the receipt of a complete application	
Performance result	New: 56% of applications were processed within the service standard Renew: 100% of applications were processed within the service standard	

#### **Medical Device Establishment Licensing Fees**

A Medical Device Establishment Licence (MDEL) is required for the activities of importing or selling medical devices for human use in Canada with exceptions<sup>a</sup>. A fee is charged for the examination of an MDEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The MDEL fee is a flat fee. The same fee is charged for an application for a new MDEL, an annual licence review of an MDEL, and the reinstatement of a suspended MDEL.

Fee grouping	Medical Device Establishment Licence Fee
Fee	Application for new licence and annual review of licence
Fee-setting authority: 2018 to 2019	<ul> <li>Financial Administration Act (FAA)<sup>ii</sup></li> <li>Fees in Respect of Drugs and Medical Devices         Regulations<sup>iii</sup></li> </ul>
Fee-setting authority: 2019	<b>2019 to 2020</b> : same as 2018 to 2019
and onwards	2020 and onwards:
	<ul> <li>Food and Drugs Act (FDA)<sup>iv</sup></li> </ul>
	Fees in Respect of Drugs and Medical Devices Order
Year introduced	2000
Last year fee-setting authority was amended	2019
Fee type	Licence
Fee amount (\$)	8,272
Total fee revenue (\$)	8,241,721
Adjustment type	Annual
Adjustment rate (% or formula)	Not applicable, updated fee as of April 1 2020
2020 to 2021 fee amount (\$)	4,590
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable, updated fee as of April 1 2020
Fee-adjustment authority	Fees in Respect of Drugs and Medical Devices Order <sup>v</sup>

<sup>&</sup>lt;sup>a</sup> As per the *Medical Devices Regulations*, an MDEL is not required for: a retailer, a health care facility, a manufacturer of Class II, III or IV medical devices who only sells either medical devices for which they hold a valid licence, or medical devices subject to Parts 2 and 3 of the Regulations, a manufacturer of a Class I medical device who imports or distributes solely through a licensed establishment, a person solely selling medical devices subject to Parts 2 and 3 of the Regulations, or a dispenser.

Service standard	120 Calendar days to issue/ renew licence
Performance result	Average number of days: 28 days

## Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product

No person shall manufacture, possess, handle, store, transport, import, distribute or use a pest control product that is not registered under the Pest Control Products Act, except as otherwise authorized under the Act or unless specifically exempted by the Pest Control Products Regulations. Fees for applications to register or to amend the registration of a pest control product are payable by component submitted. The fee payable is the sum of the fees for the submitted components in addition to the basic processing fee.

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category A Component Based – 655 Days of Review (Conventional Chemicals and Import Maximum Residue Limits)	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	77,324
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014

	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	17,848
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	5,874
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	43,539
	Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	24,110
	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	38,023
	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	24,164
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Specification of maximum residue limit for a previously unexamined pest control product <sup>xvi</sup>	127,971
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,155
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	

2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	80,449
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,173
	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient	18,570
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	6,112
	Metabolism data <sup>xv</sup>	30,716
	Residue data <sup>xv</sup>	16,809
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	45,299
	Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	25,085
	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	39,560
	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	25,141
	Value and effectiveness data for a pest control product <sup>xv</sup>	963

	Specification of maximum residue limit for a previously unexamined pest control product <sup>xvi</sup>	133,142
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,809
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	655 Days of Review	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category A Component Based – 555 Days (Reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)	
Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	77,324

Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	17,848
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	5,874
Metabolism data <sup>xv</sup>	29,522
Residue data <sup>xv</sup>	16,155
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	43,539
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary**	24,110
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	38,023
Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	24,164
Value and effectiveness data for a pest control product <sup>xv</sup>	925
Registration of a new active ingredient – food usexvii	7,381
Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,428
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	2,952

	Processingxiv	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	80,449
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,173
	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	18,570
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	6,112
	Metabolism dataxv	30,716
	Residue data <sup>xv</sup>	16,809
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	45,299
	Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	25,085
	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	39,560

	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	25,141
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Registration of a new active ingredient – food use <sup>xvii</sup>	7,680
	Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,608
	Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	3,073
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	555 Days of Review	
Performance result	100% (1/1 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category A Component Based – 470 Days of Review (Microbials including User Requested Minor Use Registration (URMUR), and URMUR for conventional chemical, reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Year introduced	1997

Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	77,324
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	17,848
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	5,874
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	43,539
	Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	24,110
	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	38,023

	F. Commercial Control and Cont	
	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	24,164
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Registration of a new active ingredient – food use <sup>xvii</sup>	7,381
	Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,428
	Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	2,952
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	80,449
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,173
	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	18,570
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	6,112

	Metabolism data <sup>xv</sup>	30,716
	Residue data <sup>xv</sup>	16,809
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	45,299
	Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	25,085
	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	39,560
	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	25,141
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Registration of a new active ingredient – food use <sup>xvii</sup>	7,680
	Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,608
	Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	3,073
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv	
Service standard	470 Days of Review	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category A Component Based – 285 Days of Review (Non- straight-chain lepidopteran pheromones, including User Requested Minor Use Registration)	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulationsxiv	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Registration of new active ingredient <sup>xvii</sup>	591
	Amendment of registration <sup>xvii</sup>	296
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Registration of new active ingredient <sup>xvii</sup>	616
	Amendment of registration <sup>xvii</sup>	309
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	285 Days of Review	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category A Component Based – Submissions with atypical timelines and joint reviews

Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019		
	Pest Control Products Fees and Charges Regulations <sup>XIV</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup>	
ua 01.11 a.	Pest Control Products Fees and Charges Regulations <sup>XIV</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	77,324
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
	Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	17,848
	Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	5,874
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	43,539
	Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	24,110

	Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	38,023
	Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	24,164
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Registration of a new active ingredient – food use <sup>xvii</sup>	7,381
	Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,428
	Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	2,952
	Registration of new active ingredient <sup>xvii</sup>	591
	Amendment of registration <sup>xvii</sup>	296
	Specification of maximum residue limit for a previously unexamined pest control product <sup>xvi</sup>	127,971
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,155
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product that contains a new active ingredient <sup>xv</sup>	80,449

Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
Toxicology data-acute toxicity studies <sup>xv</sup>	3,173
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient <sup>xv</sup>	18,570
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	6,112
Metabolism data <sup>xv</sup>	30,716
Residue data <sup>xv</sup>	16,809
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	45,299
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary <sup>xv</sup>	25,085
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient <sup>xv</sup>	39,560
Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary <sup>xv</sup>	25,141
Value and effectiveness data for a pest control product <sup>xv</sup>	963
Registration of a new active ingredient – food use <sup>xvii</sup>	7,680
Registration of a new active ingredient – non-food use <sup>xvii</sup>	4,608
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data <sup>xvii</sup>	3,073

	Registration of new active ingredient <sup>xvii</sup>	616
	Amendment of registration <sup>xvii</sup>	309
	Specification of maximum residue limit for a previously unexamined pest control product <sup>xvi</sup>	133,142
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,809
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	Variable as per Management of Submission Policy <sup>xviii</sup> Appendix I, Table 1	
Performance result	100% (1/1 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in I a Pest Control Product	Respect of
Fee	Category B Component Based – 425 Days of Review (Conventional Chemicals including emergency use and New Import Maximum Residue Limits for previously assessed active ingredient)	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768

	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>XV</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
	Exposure data - other <sup>xv</sup>	5,319
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - otherxv	11,777
	Environmental toxicology data - otherxv	2,515
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,155
	Processingxiv	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,137
	Exposure data - other <sup>xv</sup>	5,535
		00.740
	Metabolism data <sup>xv</sup>	30,716
	Metabolism data <sup>xv</sup> Residue data <sup>xv</sup>	16,809

	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,809
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	425 Days of Review	
Performance result	87% (111/128 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category B Component Based – 360 Days of Review (Reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone including emergency use)	
Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019	Pest Control Products Fees and Charges Regulationsxiv	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredientxv	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studiesxv	3,014

	Exposure data - otherxv	5,319
	·	5,519
	Metabolism dataxv	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - otherxv	11,777
	Environmental toxicology data - otherxv	2,515
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – data required, other <sup>xvii</sup>	1,182
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,137
	Exposure data - otherxv	5,535
	Metabolism dataxv	30,716
	Residue data <sup>xv</sup>	16,809
	Environmental fate data - otherxv	12,254
	Environmental toxicology data - otherxv	2,618
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,537

	Amendment of registration – data required, otherxvii	1,231
	Processingxiv	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv	
Service standard	360 Days of Review	
Performance result	83% (10/12 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category B Component Based – 240 Days of Review (Microbials and straight chain lepidopteran pheromones including emergency use)	
Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019	Pest Control Products Fees and Charges Regulationsxiv	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – data required, otherxvii	1,182
	Amendment of registration <sup>xvii</sup>	296
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate	2% (rounded up to the nearest dollar)	
(% or formula)		
2020 to 2021 fee amount (\$)	Amendment of registration – data required, label changes <sup>xvii</sup>	1,537

	Amendment of registration – data required, otherxvii	1,231
	Amendment of registration <sup>xvii</sup>	309
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	240 Days of Review	
Performance result	100% (20/20 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category B Component Based – 158 Days of Review (Streamlined; application rate changes, tank mixes, new pests or changes to level of control)	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – no data required, otherxvii	296
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	

2020 to 2021 fee amount (\$)	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,537
	Amendment of registration – no data required, otherxvii	309
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	158 Days of Review	
Performance result	96% (49/51 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category B Component Based – Submissions with atypical timelines and joint reviews	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014

	Exposure data-other <sup>xv</sup>	5,319
	Metabolism dataxv	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - other <sup>xv</sup>	11,777
	Environmental toxicology data - otherxv	2,515
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Amendment of registration - data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration - data required, otherxvii	1,182
	Amendment of registration - no data required <sup>xvii</sup>	296
	Amendment of registration <sup>xvii</sup>	296
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,155
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,137
	Exposure data-other <sup>xv</sup>	5,535
	Metabolism data <sup>xv</sup>	30,716
	Residue data <sup>xv</sup>	16,809
	Environmental fate data - otherxv	12,254

	Environmental toxicology data - otherxv	2,618
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Amendment of registration - data required, label changes <sup>xvii</sup>	1,537
	Amendment of registration - data required, otherxvii	1,231
	Amendment of registration - no data required <sup>xvii</sup>	309
	Amendment of registration <sup>xvii</sup>	309
	Specification of maximum residue limit for an unregistered use of a previously examined pest control product <sup>xvi</sup>	16,809
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	Variable as per Management of Submission Policy <sup>xviii</sup> Appendix I, Table 2	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category C Component Based – 240 Days of Review (New/Changes to Product Labels, Addition of Approved Minor Use, Similar Product)
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Year introduced	1997
Last year fee-setting authority was amended	2017

Fee type	Service	
Fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	296
	Amendment of registration xvii	296
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	309
	Amendment of registration xvii	309
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	240 Days of Review	
Performance result	95% (570/599 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product
Fee	Category C Component Based – 180 Days of Review (New/Changes to TGAI, ISP, MA or EP Product Chemistry, Administrative Changes, Administrative Re-instatement)
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>
2019	Pest Control Products Fees and Charges Regulations xiv
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>
and onwards	Pest Control Products Fees and Charges Regulations xiv
Year introduced	1997
Last year fee-setting authority was amended	2017
Fee type	Service

Fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	296
	Amendment of registration <sup>xvii</sup>	296
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	309
	Amendment of registration <sup>xvii</sup>	309
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	180 Days of Review	
Performance result	93% (120/129 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category C Component Based – Submissions with atypical timelines and joint reviews	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	296
	Amendment of registration <sup>xvii</sup>	296

	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Amendment of registration – no data required <sup>xvii</sup>	309
	Amendment of registration <sup>xvii</sup>	309
	Processingxiv	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	Variable as per Management of Submission Policy <sup>xviii</sup> Appendix I, Table 2	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category D Component Based – 246 Days of Review (Registration Renewal)	
Fee-setting authority: 2018 to		
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 Pest Control Products Act <sup>xiii</sup>		
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Renewal	82
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	

Adjustment rate	2% (rounded up to the nearest dollar)	
(% or formula)		
2020 to 2021 fee amount (\$)	Renewal	86
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	246 Days of Review	
Performance result	100% (973/973 applications reviewed within the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category D Component Based – 46 Days of Review (Registration/Amendment to Registration of active ingredient to be used in pest control product manufactured only for export)	
Fee-setting authority: 2018	Pest Control Products Act <sup>xiii</sup>	
to 2019	Pest Control Products Fees and Charges Regulations	xiv
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Registration of active ingredient to be used in pest control product manufactured only for export <sup>xvi</sup>	7,948
	Amendment to Registration of active ingredient to be used in pest control product manufactured only for export <sup>xvi</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	

2020 to 2021 fee amount (\$)	Registration of active ingredient to be used in pest control product manufactured only for export <sup>xvi</sup>	8,307
	Amendment to Registration of active ingredient to be used in pest control product manufactured only for export <sup>xvi</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv	
Service standard	46 Days of Review	
Performance result	100% (2/2 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category D Component Based – 42 Days of Review (	(Master Copies)
Fee-setting authority: 2018	Pest Control Products Act <sup>xiii</sup>	
to 2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulations	xiv
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Processingxiv	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate	2% (rounded up to the nearest dollar)	
(% or formula)		
2020 to 2021 fee amount (\$)	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	

Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv
Service standard	42 Days of Review
Performance result	91% (50/55 applications met the service standard)

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category D Component Based – 10 Days of Review (Private Labels)	
Fee-setting authority: 2018	Pest Control Products Act <sup>xiii</sup>	
to 2019	Pest Control Products Fees and Charges Regulationsxiv	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulations	Sxiv
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Processingxiv	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Processing <sup>xiv</sup>	1,204
	•	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	10 Days of Review	
Performance result	100% (2/2 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of
	a Pest Control Product

Fee	Category E Component Based – 159 Days of Review (Re Authorizations for New Technical Grade Active Ingredient	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,182
	Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,182
	Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations <sup>xvi</sup>	1,242
	Research authorization – greenhouse crops and non- agricultural uses <sup>xvi</sup>	1,242
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,392
	Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,392
	Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations <sup>xvi</sup>	1,293

	Research authorization – greenhouse crops and non-agricultural uses <sup>xvi</sup>	1,293
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv	
Service standard	159 Days of Review	
Performance result	33% (12/36 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category E Component Based – 69 Days of Review (Research Authorizations for New Uses of Registered Active Ingredients)	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulations xiv	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,182
	Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	5,182
	Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations <sup>xvi</sup>	1,242
	Research authorization – greenhouse crops and non- agricultural uses <sup>xvi</sup>	1,242
Total fee revenue (\$)	No data available at this time	

Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	,392
	Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d) <sup>xvi</sup>	,392
	Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations <sup>xvi</sup>	,293
	Research authorization – greenhouse crops and non- agricultural uses <sup>xvi</sup>	,293
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	69 Days of Review	
Performance result	13% (5/40 applications met the service standard)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category E Component Based – 30 Days of Review (Research Notification for Research Carried out in Canada)	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Research notifications <sup>xvi</sup>	252

Total fee revenue (\$)	No data available at this time
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)
2020 to 2021 fee amount (\$)	Research notifications <sup>xvi</sup> 264
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv
Service standard	30 Days of Review
Performance result	50% (13/26 applications met the service standard)

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category F Component Based – 45 Days of Review (Registration and amendments to registered pest control products via notification)	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Applications not mentioned in schedules	252
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Applications not mentioned in schedules	264

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Service standard	45 Days of Review
Performance result	98% (822/842 applications met the service standard)

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category L Component Based – 425 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - conventional chemical)	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
	Exposure data - other <sup>xv</sup>	5,319
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - otherxv	11,777

	Environmental toxicology data – other xv	2,515
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Identification of compensable dataxv	2,206
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,137
	Exposure data - otherxv	5,535
	Metabolism data <sup>xv</sup>	30,716
	Residue data <sup>xv</sup>	16,809
	Environmental fate data - otherxv	12,254
	Environmental toxicology data – other xv	2,618
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Identification of compensable dataxv	2,297
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulationsxiv	
Service standard	425 Days of Review	

Performance result	86% (18/21 applications met the service standard)
--------------------	---

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category L Component Based – 365 Days of Review (Equivalency and data compensation assessment of active ingredient, end-use product and manufacturing concentrate with no data)	
Fee-setting authority: 2018 to	Pest Control Products Act <sup>xiii</sup>	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Act <sup>xiii</sup>	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Identification of compensable dataxv	2,206
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Identification of compensable dataxv	2,297
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	

Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Service standard	365 Days of Review
Performance result	97% (61/63 applications met the service standard)

Fee grouping	Fees to be Paid for the Examination of an Application in R	espect of
- r cc grouping	a Pest Control Product	
Fee	Category L Component Based – 360 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone)	
Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	4,971
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014
	Exposure data - otherxv	5,319
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - otherxv	11,777
	Environmental toxicology data – other <sup>xv</sup>	2,515

	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Identification of compensable dataxv	2,206
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – data required, otherxvii	1,182
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup>	5,173
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,881
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,800
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,137
	Exposure data - other <sup>xv</sup>	5,535
	Metabolism data <sup>xv</sup>	30,716
	Residue data <sup>xv</sup>	16,809
	Environmental fate data - otherxv	12,254
	Environmental toxicology data – otherxv	2,618
	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Identification of compensable dataxv	2,297
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,537
	Amendment of registration – data required, otherxvii	1,231
	Processing <sup>xiv</sup>	1,204

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations xiv
Service standard	360 Days of Review
Performance result	N/A (0 applications completed in 2018-19)

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category L Component Based 240 Days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - microbials and straight chain lepidopteran pheromone)	
Fee-setting authority: 2018 to	Pest Control Products Actxiii	
2019	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019	Pest Control Products Actxiii	
and onwards	Pest Control Products Fees and Charges Regulationsxiv	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Identification of compensable dataxv	2,206
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – data required, otherxvii	1,182
	Amendment of registrationxviii	296
	Processing <sup>xiv</sup>	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
2020 to 2021 fee amount (\$)	Identification of compensable data <sup>xv</sup> 2,297	

	Amendment of registration – data required, label changes <sup>xvii</sup>	1,537
	Amendment of registration – data required, otherxvii	1,231
	Amendment of registration <sup>xvii</sup>	309
	Processing <sup>xiv</sup>	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	240 Days of Review	
Performance result	N/A (0 applications completed in 2018-19)	

Fee grouping	Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product	
Fee	Category L Component Based – Applications with atypical timelines (Tailgaters, renegotiated timelines, synchronized timelines, coordination with Re-Evaluation)	
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Year introduced	1997	
Last year fee-setting authority was amended	2017	
Fee type	Service	
Fee amount (\$)	Product Chemistry – active ingredient <sup>xv</sup> 4,971	
	Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup>	2,768
	Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	16,147
	Toxicology data-acute toxicity studies <sup>xv</sup>	3,014

	Exposure data - otherxv	5.040
	·	5,319
	Metabolism data <sup>xv</sup>	29,522
	Residue data <sup>xv</sup>	16,155
	Environmental fate data - otherxv	11,777
	Environmental toxicology data – otherxv	2,515
	Value and effectiveness data for a pest control product <sup>xv</sup>	925
	Identification of compensable dataxv	2,206
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,476
	Amendment of registration – data required, otherxvii	1,182
	Amendment of registration <sup>xvii</sup>	296
	Processingxiv	1,156
Total fee revenue (\$)	No data available at this time	
Adjustment type	Annual	
Adjustment rate (% or formula)	2% (rounded up to the nearest dollar)	
		5,173
(% or formula)	2% (rounded up to the nearest dollar)	5,173 2,881
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing	
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup> Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active	2,881
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup> Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup>	2,881 16,800
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup> Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup> Toxicology data-acute toxicity studies <sup>xv</sup>	2,881 16,800 3,137
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup> Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup> Toxicology data-acute toxicity studies <sup>xv</sup> Exposure data - other <sup>xv</sup>	2,881 16,800 3,137 5,535
(% or formula)	2% (rounded up to the nearest dollar)  Product Chemistry – active ingredient <sup>xv</sup> Product Chemistry – end-use product or manufacturing concentrate <sup>xv</sup> Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient <sup>xv</sup> Toxicology data-acute toxicity studies <sup>xv</sup> Exposure data - other <sup>xv</sup> Metabolism data <sup>xv</sup>	2,881 16,800 3,137 5,535 30,716

	Value and effectiveness data for a pest control product <sup>xv</sup>	963
	Identification of compensable dataxv	2,297
	Amendment of registration – data required, label changes <sup>xvii</sup>	1,231
	Amendment of registration – data required, otherxvii	1,182
	Amendment of registration <sup>xvii</sup>	309
	Processingxiv	1,204
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Pest Control Products Fees and Charges Regulations <sup>xiv</sup>	
Service standard	Variable as per Management of Submission Policy <sup>xviii</sup> Appendix I, Table 7	
Performance result	N/A (0 applications completed in 2018-19)	

## **Annual Charge (for a registered Pest Control Product)**

A registrant must pay each year, in respect of every pest control product that is registered in their name on April 1 of the year, an annual charge. All registered products including technical grade active ingredients (TGAI), import for manufacturing and export program (IMEPs), private label products and master copies must pay the annual charge.

Fee grouping	Annual Charge (for a registered Pest Control Product)
Fee	Annual Charge
Fee-setting authority: 2018 to 2019	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Fee-setting authority: 2019 and onwards	Pest Control Products Act <sup>xiii</sup> Pest Control Products Fees and Charges Regulations <sup>xiv</sup>
Year introduced	1997
Last year fee-setting authority was amended	2017
Fee type	Other Authorization

Fee amount (\$)	The lesser of \$3,600 and 4% of the actual gross revenue during the registrant's preceding fiscal year, but not less than \$100
Total fee revenue (\$)	\$9,432,992
Adjustment type	Annual
Adjustment rate (% or formula)	2%
2020 to 2021 fee amount (\$)	The lesser of \$3,752.78 and 4% of the actual gross revenue during the registrant's preceding fiscal year, but not less than \$104.24.
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Section 17 of the Service Fees Act (Consumer Price Index)
Service standard	100% of all invoices were issued by April 30 <sup>th</sup> 2018
Performance result	100%

## Fees Charged for Filing a Claim for Exemption Under the Hazardous Materials Information Review Act

When a supplier or employer wants to be exempt from having to disclose confidential business information (CBI), such as the chemical identity of one or more trade-secret hazardous ingredients, they must file a claim for exemption with Health Canada.

Fee grouping	Fees Charged for Filing a Claim for Exemption Under the Hazardous Materials Information Review Act	
Fee	Original Claims	
Fee-setting authority: 2018 to 2019	<ul> <li>Hazardous Materials Information Review Act<sup>xix</sup></li> <li>Hazardous Materials Information Review Regulations<sup>xx</sup></li> </ul>	
Fee-setting authority: 2019 and onwards	<ul> <li>Hazardous Materials Information Review Act<sup>xix</sup></li> <li>Hazardous Materials Information Review Regulations<sup>xx</sup></li> </ul>	
Year introduced	1988	
Last year fee-setting authority was amended	2002	
Fee type	Service	
Fee amount (\$)	Original Claim (up to 15) 1,800	
	Original Claim (between 16-25) 400	
	Original Claim (26+)	

	A 50% reduction for a small business that meets certain criteria is available	
Total fee revenue (\$)	346,674	
Adjustment type	Section 17 of the Service Fees Act (Consumer Price Index)	
Adjustment rate (% or formula)	2%	
2020 to 2021 fee amount (\$)	Original Claim (up to 15)	1,876.39
	Original Claim (between 16-25)	416.98
	Original Claim (26+)	208.49
	A 50% reduction for a small business that meets certain criteria is available.	
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Service Fees Act	
Service standard	7 calendar days from the date of the receipt of a complete application, for the issuance of a registry number	
Performance result	99% of claims (original and refiled) were completed within the service standard	

Fee grouping	Fees Charged for Filing a Claim for Exemption Under the Hazardous Materials Information Review Act	
Fee	Refiled Claims	
Fee-setting authority: 2018 to 2019	<ul> <li>Hazardous Materials Information Review Act<sup>xix</sup></li> <li>Hazardous Materials Information Review Regulations<sup>xx</sup></li> </ul>	
Fee-setting authority: 2019 and onwards	<ul> <li>Hazardous Materials Information Review Act<sup>xix</sup></li> <li>Hazardous Materials Information Review Regulations<sup>xx</sup></li> </ul>	
Year introduced	1988	
Last year fee-setting authority was amended	2002	
Fee type	Service	
Fee amount (\$)	Refiled Claims (up to 15) 1,440	
	Refiled Claims (between 16-25) 320	
	Refiled Claims (26+) 160	

	A 50% reduction for a small business that meets of available	certain criteria is
Total fee revenue (\$)	112,320	
Adjustment type	Section 17 of the Service Fees Act (Consumer Pri	ice Index)
Adjustment rate (% or formula)	2%	
2020 to 2021 fee amount (\$)	Refiled Claims (up to 15)	1,501.11
	Refiled Claims (between 16-25)	333.58
	Refiled Claims (26+)	166.79
	A 50% reduction for a small business that meets of available.	certain criteria is
Future fee-adjusted amount (\$)	Not applicable	
Adjustment date	April 1, 2020	
Fee-adjustment authority	Service Fees Act	
Service standard	7 calendar days from the date of the receipt of a complete application, for the issuance of a registry number	
Performance result	99% of claims (original and refiled) were complete service standard	ed within the

## **Cannabis Fees**

Fees are charged for the following transactional activities: application screening, security clearances, and import/export permits. In addition, an Annual Regulatory Fee is charged which covers costs associated with a range of regulatory activities including regulatory inspections, compliance and enforcement, program management and oversight. These activities are carried out by Health Canada, the Canada Border Services Agency, the Public Health Agency of Canada and Public Safety Canada to support the objectives of the *Cannabis Act* with respect to the legislation and regulations of cannabis.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for micro-cultivation
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018

Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>
Fee amount (\$)	1,638
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	1,709
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup> (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for standard cultivation
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>

<sup>&</sup>lt;sup>b</sup> The application screening fee relates to the recovery of costs associated with the intake, screening, acceptance or rejection of new applications for certain licensed activities; the acceptance of the licence application indicates that the application will proceed to the next phase of licence review and does not mean that a new licence will be issued.

Fee amount (\$)	3,277
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	3,417
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Orderxxii (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for a nursery
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>
Fee amount (\$)	1,638
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate	2% (rounded to the next highest dollar)
(% or formula)	
2020 to 2021 fee amount (\$)	1,709

Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup> (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for micro-processing
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>
Fee amount (\$)	1,638
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	1,709
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Orderxxii (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the

	application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for standard processing
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>
Fee amount (\$)	3,277
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	3,417
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup> (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Licence Application Screening Fee - Licence for sale for medical purposes
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>b</sup>
Fee amount (\$)	3,277
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	3,417
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup> (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days for the screening of licence applications from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Application for a security clearance
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>

Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Other Authorization
Fee amount (\$)	1,654
Total fee revenue (\$)	Data not available
Adjustment type	Annual
Adjustment rate (% or formula)	2% (rounded to the next highest dollar)
2020 to 2021 fee amount (\$)	1,725
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Orderxxii (Consumer Price Index)
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the <i>Cannabis Fees Order</i> .
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Application for import or export permit
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Permit
Fee amount (\$)	610
Total fee revenue (\$)	Data not available
Adjustment type	Annual

Adjustment rate	2% (rounded to the next highest dollar)
(% or formula)	
2020 to 2021 fee amount (\$)	637
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	April 1, 2020
Fee-adjustment authority	Cannabis Fees Order xxii (Consumer Price Index)
Service standard	Health Canada is committed to a non-binding administrative service standard of 30 business days from the date that payment is received for the application. The standard excludes time spent awaiting additional information from applicants.
Performance result	As the <i>Cannabis Fees Order</i> came into force on October 17, 2018, the full fiscal year of data is not available.

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for micro-cultivation
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate	Not applicable as the fee is based on cannabis revenue

<sup>&</sup>lt;sup>c</sup> The annual regulatory fee recovers the aggregate costs of administering the cannabis regulatory program that are not covered under any of the other fees. The annual regulatory fee is payable annually by cultivation, processing and federal sales licence holders

(% or formula)	
2020 to 2021 fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue
Fee-adjustment authority	Cannabis Fees Orderxxii (Consumer Price Index)
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the <i>Cannabis Fees Order</i> .
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for standard cultivation
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate (% or formula)	Not applicable as the fee is based on cannabis revenue
2020 to 2021 fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue

Fee-adjustment authority	Cannabis Fees Order*xxii(Consumer Price Index)
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the Cannabis Fees Order.
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for a nursery
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate (% or formula)	Not applicable as the fee is based on cannabis revenue
2020 to 2021 fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, , the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup>

Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the Cannabis Fees Order.
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for micro-processing
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>exi</sup></li> <li>Cannabis Fees Order<sup>exii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate (% or formula)	Not applicable as the fee is based on cannabis revenue
2020 to 2021 fee amount (\$)	(a) If the cannabis revenue is \$1 million or less, the greater of 1% of the cannabis revenue, and \$2,500; or
	(b) if the cannabis revenue is greater than \$1 million, the maximum amount determinable under (a) plus 2.3% of the amount by which the cannabis revenue exceeds \$1 million
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup>

Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the Cannabis Fees Order.
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for standard processing
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate (% or formula)	Not applicable as the fee is based on cannabis revenue
2020 to 2021 fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup>
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the Cannabis Fees Order.
Performance result	Not applicable

Fee grouping	Cannabis Fees
Fee	Annual fee - Licence for medical purposes
Fee-setting authority: 2018 to 2019	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Fee-setting authority: 2019 and onwards	<ul> <li>Cannabis Act<sup>xxi</sup></li> <li>Cannabis Fees Order<sup>xxii</sup></li> </ul>
Year introduced	2018
Last year fee-setting authority was amended	Not applicable
Fee type	Licence <sup>c</sup>
Fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Total fee revenue (\$)	Data not available
Adjustment type	Exempt
Adjustment rate (% or formula)	Not applicable as the fee is based on cannabis revenue
2020 to 2021 fee amount (\$)	The greater of 2.3% of the cannabis revenue and \$23,000
Future fee-adjusted amount (\$)	Not applicable
Adjustment date	Not applicable as the fee is based on cannabis revenue
Fee-adjustment authority	Cannabis Fees Order <sup>xxii</sup>
Service standard	No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the Cannabis Fees Order.
Performance result	Not applicable

## **Endnotes**

<sup>i</sup> Service Fees Act, https://laws-lois.justice.gc.ca/eng/acts/S-8.4/index.html

- <sup>v</sup> Fees in Respect of Drugs and Medical Devices Order, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-124/FullText.html
- vi Authority to Sell Veterinary Drug Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-95-31/index.html
- vii Patent Act, https://laws-lois.justice.gc.ca/eng/acts/p-4/index.html
- viii Certificate of Supplementary Protection Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-165/FullText.html
- ix Veterinary Drug Evaluation Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-96-143/page-1.html
- <sup>x</sup> Establishment Licensing Fees (Veterinary Drugs) Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-4/page-1.html
- xi Fees in Respect of a Dealer's Licences Regulations, (SOR/2019-134) https://laws-lois.justice.gc.ca/eng/regulations/sor-2011-79/nifnev.html?wbdisable=true
- xii Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-5/page-1.html
- xiii Pest Control Products Act, https://laws-lois.justice.gc.ca/eng/acts/p-9.01/
- xiv Pest Control Products Fees and Charges Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-9/page-2.html#h-843610
- xv Pest Control Products Fees and Charges Regulations Schedule 1, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-9/page-3.html
- xvi Pest Control Products Fees and Charges Regulations Schedule 3, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-9/page-5.html#docCont
- xvii Pest Control Products Fees and Charges Regulations Schedule 2, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-9/page-4.html#docCont
- xviii Management of Submission Policy, https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/regulatory-directive/2017/dir2017-01-management-submissions-policy.html
- xix Hazardous Materials Information Review Act, https://laws-lois.justice.gc.ca/eng/acts/h-2.7/index.html

ii Financial Administration Act (FAA), https://laws-lois.justice.gc.ca/eng/acts/f-11/

iii Fees in Respect of Drugs and Medical Devices Regulations, https://laws-lois.justice.gc.ca/eng/regulations/sor-2011-79/index.html

iv Food and Drugs Act (FDA), https://laws-lois.justice.gc.ca/eng/acts/f-27/

xx Hazardous Materials Information Review Regulations, https://lawslois.justice.gc.ca/eng/regulations/sor-88-456/

xxi Cannabis Act, https://laws-lois.justice.gc.ca/eng/acts/c-24.5/

xxii Cannabis Fees Order, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-198/page-1.html